Novartis Lp(a) drug misses heart-event goal in large trial
Pelacarsen lowered lipoprotein(a) but did not cut a composite of heart death, heart attack, stroke and urgent revascularization versus placebo in Phase III, Novartis said; full data were presented Saturday.
What's new
- Reuters is now reporting this
- New headline Was: “A promising new medicine against heart disease fails unexpectedly”
- Our desk filed its story
